𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Clinical experience with the NIR stent: Retrospective observation on acute results and follow-up in 709 patients

✍ Scribed by Alberto Cremonesi; Alessandro Alberti; Fausto Castriota; Enrico Ricci; Bilal El Jamal; Chiara Grattoni; Raffaella Manetti; Cristina Nannini; Claudia Filippini

Publisher
Springer
Year
2011
Tongue
English
Weight
779 KB
Volume
9
Category
Article
ISSN
1061-1711

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Initial clinical experience with the new
Initial clinical experience with the new EBI (BARD-XT) flexible coronary stent: Acute results and follow-up
✍ Sievert, Horst ;Rohde, Stephan ;Ensslen, Roland ;Fach, Andreas ;Merle, Hartmut ; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 1 views

The EBI (BARD-XT, C.R. Bard, Murray Hill, NJ) stent is a new radiopaque balloon expandable coronary stent with high resistance to external radial forces. It does not shorten significantly with expansion and allows stent implantation in bifurcation lesions. A total of 28 EBI stents were implanted in

Preliminary experience with stent-suppor
Preliminary experience with stent-supported coronary angioplasty in long narrowings using the long freedom force stent: Acute and six-month clinical and angiographic results in a series of 27 consecutive patients
✍ Antoniucci, David ;Valenti, Renato ;Santoro, Giovanni Maria ;Bolognese, Leonardo 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 2 views

This report describes our preliminary experience with coronary stent-supported angioplasty in long narrowings using a long stent with an innovative design. Twenty-seven consecutive patients with target lesions G20 mm in length had a stenting procedure using the Freedom Force long coronary stent (Glo

Four-year clinical follow-up of the XIEN
Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: The SPIRIT II trial
✍ Scot Garg; Patrick W. Serruys; Karine Miquel-Hebert; on behalf of the SPIRIT II 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 2 views

## Abstract This report describes the 4‐year clinical outcomes of the SPIRIT II study, which randomized 300 patients to treatment with the XIENCE V everolimus‐eluting stent (EES), or the TAXUS paclitaxel‐eluting stent. At 4‐year clinical follow‐up, which was available in 256 (85.3%) patients, treat